GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lifecore Biomedical Inc (NAS:LFCR) » Definitions » Cyclically Adjusted Revenue per Share

Lifecore Biomedical (Lifecore Biomedical) Cyclically Adjusted Revenue per Share : $16.60 (As of May. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Lifecore Biomedical Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Lifecore Biomedical's adjusted revenue per share for the three months ended in May. 2023 was $0.842. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $16.60 for the trailing ten years ended in May. 2023.

During the past 12 months, Lifecore Biomedical's average Cyclically Adjusted Revenue Growth Rate was -5.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 1.00% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 4.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Lifecore Biomedical was 9.70% per year. The lowest was 1.00% per year. And the median was 6.00% per year.

As of today (2024-04-27), Lifecore Biomedical's current stock price is $6.595. Lifecore Biomedical's Cyclically Adjusted Revenue per Share for the quarter that ended in May. 2023 was $16.60. Lifecore Biomedical's Cyclically Adjusted PS Ratio of today is 0.40.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Lifecore Biomedical was 1.41. The lowest was 0.10. And the median was 0.79.


Lifecore Biomedical Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Lifecore Biomedical's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lifecore Biomedical Cyclically Adjusted Revenue per Share Chart

Lifecore Biomedical Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.10 16.61 17.18 17.61 16.60

Lifecore Biomedical Quarterly Data
Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.61 17.48 17.15 16.85 16.60

Competitive Comparison of Lifecore Biomedical's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lifecore Biomedical's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Lifecore Biomedical's Cyclically Adjusted PS Ratio falls into.



Lifecore Biomedical Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lifecore Biomedical's adjusted Revenue per Share data for the three months ended in May. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of May. 2023 (Change)*Current CPI (May. 2023)
=0.842/128.3144*128.3144
=0.842

Current CPI (May. 2023) = 128.3144.

Lifecore Biomedical Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201308 4.043 98.675 5.257
201311 4.434 98.334 5.786
201402 4.659 99.057 6.035
201405 4.446 100.373 5.684
201408 4.900 100.352 6.265
201411 4.857 99.635 6.255
201502 5.063 99.032 6.560
201505 4.907 100.333 6.276
201508 4.938 100.548 6.302
201511 5.122 100.135 6.563
201602 4.805 100.040 6.163
201605 2.625 101.355 3.323
201608 4.811 101.617 6.075
201611 4.919 101.829 6.198
201702 4.933 102.779 6.159
201705 2.338 103.256 2.905
201708 4.156 103.587 5.148
201711 4.393 104.072 5.416
201802 5.191 105.052 6.340
201805 5.037 106.148 6.089
201808 4.449 106.383 5.366
201811 4.486 106.338 5.413
201902 5.336 106.649 6.420
201905 5.227 108.048 6.207
201908 4.760 108.245 5.643
201911 4.891 108.519 5.783
202002 5.243 109.139 6.164
202005 -9.395 108.175 -11.144
202008 4.639 109.662 5.428
202011 4.471 109.793 5.225
202102 1.524 110.968 1.762
202105 -0.878 113.576 -0.992
202108 1.415 115.421 1.573
202111 1.474 117.269 1.613
202202 1.269 119.703 1.360
202205 0.717 123.323 0.746
202208 1.466 124.958 1.505
202211 1.309 125.607 1.337
202302 0.911 126.928 0.921
202305 0.842 128.314 0.842

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Lifecore Biomedical  (NAS:LFCR) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Lifecore Biomedical's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=6.595/16.6
=0.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Lifecore Biomedical was 1.41. The lowest was 0.10. And the median was 0.79.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Lifecore Biomedical Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Lifecore Biomedical's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Lifecore Biomedical (Lifecore Biomedical) Business Description

Industry
Traded in Other Exchanges
N/A
Address
3515 Lyman Boulevard, Chaska, MN, USA, 55318
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid.
Executives
Raymond T. White director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Holdings, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. Ii director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. I director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Asset Management, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Christopher S Kiper director 12121 WILSHIRE BLVD, SUITE 1240, LOS ANGELES CA 90025
Nathaniel Calloway director C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Wynnefield Partners Small Cap Value Lp I 10 percent owner 450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123
Raymond H Diradoorian director C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Joshua Schechter director C/O THE PANTRY, INC., 305 GREGSON DRIVE, CARY NC 27511
Patrick D Walsh director 14282 FRANKLIN AVE., TUSTIN CA 92780
John D Morberg officer: Chief Financial Officer C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Albert D. Bolles director CONAGRA FOODS, INC., ONE CONAGRA DRIVE, MS 1-330, OMAHA NE 68102
James G Hall officer: Executive Vice President 3515 LYMAN BLVD., CHASKA MN 55318